PARP Inhibitor competition heating up and it won't be dominated by one player for ovarian or br
"The PARP inhibitor market is going to be split. The question is to what extent, and whether insurers, pharmacy benefit managers and other payers will use this crowding to lever down drug prices." - from Bloomberg article by Max Nisen
